Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

Abstract

An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.

1 - 34 . (canceled)  
   
   
       35 . A composition for use in treating diseases, comprising: 
 from about 40% to about 60% by weight of a phytochemical concentrate of herbaceous botanicals comprising  Commiphora myrrha  and  Echinacea purpurea ; and    said phytochemical concentrate of  Commiphora myrra  and  Echinacea purpurea  providing antimicrobial isolates.    
   
   
       36 . A composition in accordance with  claim 35  including from about 20% to about 60% by weight of an aqueous diluent and carrier for said phytochemical concentrate.  
   
   
       37 . A composition in accordance with  claim 35  including: 
 from about 2% to about 12% by weight folic acid providing a nutrient; and    said folic acid cooperating with said  Commiphora myrrha  and said  Echinacea purpurea  to help treat said disease.    
   
   
       38 . A composition in accordance with  claim 35  wherein said antimicrobial isolates of said phytochemical concentrate comprise by weight based upon the total weight of the composition: 
 from about 0.3% to about 9% echinacoside;    from about 0.1% to about 7% PS I and PS II, wherein PS I is 4-O-methylglucoronoarabinoxylan, Mr 35 kD and PS II is acid rhamnoarabinogalactan, Mr 450 kD;    from about 0.1% to about 10% cynarin and chicoric acid;    from about 0.2% to about 4% echinolone;    from about 0.2% to about 8% echinacin B;    from about 0.1% to about 6% echinaceine;    from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-B-D-glucopyranoside and 3-O-(6-O-malonyl)-B-D-glucopyranoside;    from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine;    from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and      Commophora myrrha  phytochemicals comprising members selected from the group consisting of: caryophylenes, sequiterpenes, curzerenone, dihydro fuanodien-6-one, 2-methoxyfuradine, elemol, lyndesterene, acetic acid, alpha-amyrone, arabinose, alpha-bisabolene, gamma-bisabolene, cadinene, campesterol, cholesterol, cinnamaldehyde, commiferin, alpha-commiphoric acid, beta-commiphoric acid, gama-commiphoric acid, commiphorinic acid, m-cresol, cumic alcohol, cuminaldehyde, dipentene, 3-epi-alpha-amyrin, eugenol, furanodiene, furanodienone, galactose, gum, heerabolene, alpha-heerabomyrrhol, beta-heerabomyrrhol, heeraboresene, limonene, 4-O-methyl-glucuronic acid, n-nonacesane, beta-sitosterol, and xylose.    
   
   
       39 . A composition for use in treating diseases, comprising: 
 from about 40% to about 60% by weight of a phytochemical concentrate of herbaceous botanicals consisting of  Commiphora myrrha  and  Echinacea purpurea;      from about 20% to about 60% by weight water providing a diluent and carrier for said phytochemical concentrate;    said antimicrobial isolates of said phytochemical concentrate comprise by weight based upon the total weight of the medical composition:    from about 0.3% to about 9% echinacoside;    from about 0.1% to about 7% PS II and PS II, wherein PS I is 4-O-methylglucoronoarabinoxylan, Mr 35 kD and PSI II is acid rhamnoarabinogalactan, Mr 450 kD;    from about 0.1% to about 10% cynarin and chicoric acid;    from about 0.2% to about 4% echinolone;    from about 0.2% to about 8% echinacin B;    from about 0.1% to about 6% echinaceine;    from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-B-D-glucopyranoside and 3-O-(6-O-malonyl)-B-D-glucopyranoside;    from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine;    from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and      Commophora myrrha  phytochemicals comprising members selected from the group consisting of: caryophylenes, sequiterpenes, curzerenone, dihydro fuanodien-6-one, 2-methoxyfuradine, elemol, lyndesterene, acetic acid, alpha-amyrone, arabinose, alpha-bisabolene, gamma-bisabolene, cadinene, campesterol, cholesterol, cinnamaldehyde, commiferin, alpha-commiphoric acid, beta-commiphoric acid, gama-commiphoric acid, commiphorinic acid, m-cresol, cumic alcohol, cuminaldehyde, dipentene, 3-epi-alpha-amyrin, eugenol, furanodiene, furanodienone, galactose, gum, heerabolene, alpha-heerabomyrrhol, beta-heerabomyrrhol, heeraboresene, limonene, 4-O-methyl-glucuronic acid, n-nonacesane, beta-sitosterol, and xylose.    
   
   
       40 . A composition in accordance with  claim 39 , wherein: 
 said antimicrobial compound further comprises by weight from about 2% to about 12% folic acid providing a nutrient; and    said folic acid cooperates with said  Commiphora myrrha  and said  Echinacea purpurea  to help treat said disease.